Search

Your search keyword '"López-Castro R"' showing total 145 results
Start Over Author "López-Castro R"
145 results on '"López-Castro R"'

2. A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial

Author

Popat, S., Curioni-Fontecedro, A., Dafni, U., Shah, R., O'Brien, M., Pope, A., Fisher, P., Spicer, J., Roy, A., Gilligan, D., Gautschi, O., Nadal, E., Janthur, W.D., López Castro, R., García Campelo, R., Rusakiewicz, S., Letovanec, I., Polydoropoulou, V., Roschitzki-Voser, H., Ruepp, B., Gasca-Ruchti, A., Peters, S., and Stahel, R.A.

Published
2020
Full Text
View/download PDF

3. P1.01-04 Clinical and Genetic Characteristics in Younger vs Older Lung Cancer Patients

Author

Candal-Pedreira, C., primary, Ruano-Ravina, A., additional, Calvo de Juan, V., additional, Cobo, M., additional, Trigo, J.M., additional, Carcereny, E., additional, Cucurull, M., additional, López Castro, R., additional, Solís García, E., additional, Sánchez-Gastaldo, A., additional, Massutí, B., additional, Rodríguez-Abreu, D., additional, Estival, A., additional, Guirado Risueño, M., additional, Rey-Brandariz, J., additional, Pamiés Ramón, M., additional, García Campelo, R., additional, Alonso-Jáudenes, G., additional, Camps, C., additional, del Barco Morillo, E., additional, González Ojea, C., additional, Dómine, M., additional, Sánchez-Hernández, A., additional, Bosch-Barrera, J., additional, Sala González, M.Á., additional, and Provencio, M., additional

Published
2023
Full Text
View/download PDF

4. PL03.12 Progression Free Survival and Overall Survival in NADIM II Study

Author

Provencio, M., primary, Serna, R., additional, Nadal, E., additional, Glez Larriba, J.L., additional, Martínez-Martí, A., additional, Bernabé, R., additional, Bosch-Barrera, J., additional, Garcia Benito, C., additional, Calvo, V., additional, Insa, A., additional, Ponce, S., additional, Reguart, N., additional, De Castro, J., additional, Massutí, B., additional, Palmero, R., additional, Aguado de la Rosa, C., additional, Mosquera, J., additional, Cobo, M., additional, Aguilar, A., additional, López Vivanco, G., additional, Camps, C., additional, Hernando Trancho, F., additional, López Castro, R., additional, Moran, T., additional, Barneto, I., additional, Rodríguez-Abreu, D., additional, and Romero, A., additional

Published
2022
Full Text
View/download PDF

5. EP08.01-029 NIVIPI-BRAIN, A Phase II Study of Nivolumab plus Ipilimumab Combined with Chemotherapy for Patients with NSCLC and Synchronous Brain Metastases

Author

Nadal, E., primary, Cantero, A., additional, Ortega, A.L., additional, Dómine, M., additional, Barba, A., additional, Blasco, A., additional, García, J., additional, Mosquera, J., additional, Vázquez, S., additional, Rodríguez, D., additional, López-Castro, R., additional, Juan-Vidal, O., additional, Sánchez, A., additional, Paz-Ares, L., additional, Hernández, A., additional, Iranzo, P., additional, Diz, P., additional, Provencio, M., additional, Simó, M., additional, Navarro, V., additional, and Bruna, J., additional

Published
2022
Full Text
View/download PDF

6. 848P Second-line systemic treatment for patients with advanced melanoma: Results from the prospective real-world study GEM1801

Author

Marquez-Rodas, I., primary, Berciano Guerrero, M.A., additional, Muñoz Couselo, E., additional, Soria, A., additional, Cerezuela-Fuentes, P., additional, Manzano Mozo, J.L., additional, Gutierrez Sanz, L., additional, Crespo, G., additional, Puértolas, T., additional, Garcia Castano, A., additional, Aguado de la Rosa, C., additional, Espinosa, E., additional, Majem Tarruella, M., additional, López Castro, R., additional, Ayala de Miguel, P., additional, Medina Martinez, J., additional, Fernández Morales, L.A., additional, Bellido Hernández, L., additional, Berrocal, A., additional, and Martín Algarra, S., additional

Published
2022
Full Text
View/download PDF

7. 802P Demography and clinical outcomes of adjuvant therapy in Spain: Results from GEM 1801 study

Author

Martín Algarra, S., primary, Piñero Madrona, A., additional, Berciano-Guerrero, M-Á., additional, Muñoz Couselo, E., additional, Soria, A., additional, Manzano, J.L., additional, Gutiérrez Sanz, L., additional, Crespo, G., additional, Puértolas, T., additional, García Castaño, A., additional, Aguado de la Rosa, C., additional, Espinosa, E., additional, Majem, M., additional, López Castro, R., additional, Ayala de Miguel, P., additional, Medina Martínez, J., additional, Fernández-Morales, L.A., additional, Bellido, L., additional, Cerezuela-Fuentes, P., additional, and Márquez-Rodas, I., additional

Published
2022
Full Text
View/download PDF

8. 837P Real-world evidence of encorafenib (E) plus binimetinib (B) in unresectable advanced or metastatic BRAFV600-mut melanoma in Spain (GEM 2002 - BECARE)

Author

Soria, A., primary, Sánchez Mauriño, P., additional, Serrano, J.J., additional, Sequero, S., additional, Fra Rodríguez, J., additional, Amezcua, V., additional, Benítez, G., additional, Espinosa, E., additional, Aguayo, C., additional, García Galindo, R., additional, Díaz-Beveridge, R., additional, Puértolas, T., additional, Cunquero-Tomás, A., additional, López Castro, R., additional, Crespo, G., additional, López, P., additional, Gutiérrez Sanz, L., additional, Campos, B., additional, García, L., additional, and Cerezuela-Fuentes, P., additional

Published
2022
Full Text
View/download PDF

9. P1.12-04 The FLARE score and circulating neutrophils are associated with poor Covid-19 outcomes in patients with thoracic cancers

Author

Seguí, E., primary, Gorria, T., additional, Auclin, E., additional, Torres, J.M., additional, Casadevall, D., additional, Aguilar-Company, J., additional, Rodríguez, M., additional, Epaillard, N., additional, Gavira, J., additional, Tapia, J.C., additional, Tagliamento, M., additional, Pilotto, S., additional, López-Castro, R., additional, Mielgo, X., additional, Urbano, C., additional, Bautista Blaquier, J., additional, Bluthgen, M.V., additional, Minatta, J.N., additional, Prat, A., additional, Vlagea, A., additional, and Mezquita, L., additional

Published
2022
Full Text
View/download PDF

10. 863P Elderly patients (pts) with advanced melanoma: Results from the prospective real-world study GEM1801

Author

Muñoz Couselo, E., primary, Ortiz Vélez, C., additional, Berciano-Guerrero, M-Á., additional, Soria, A., additional, Cerezuela-Fuentes, P., additional, Manzano, J.L., additional, Gutiérrez Sanz, L., additional, Crespo, G., additional, Puértolas, T., additional, García Castaño, A., additional, Aguado de la Rosa, C., additional, Espinosa, E., additional, Majem, M., additional, López Castro, R., additional, Ayala de Miguel, P., additional, Medina Martínez, J., additional, Fernández-Morales, L.A., additional, Bellido, L., additional, Martín Algarra, S., additional, and Márquez-Rodas, I., additional

Published
2022
Full Text
View/download PDF

11. 1158P Study of patients’ characteristics associated with osimertinib outcomes upfront or in following lines in EGFR-positive NSCLC

Author

Auclin, E., primary, Du Rusquec, P., additional, Albarran, V., additional, Aboubakar, F., additional, Gerber, H., additional, Epaillard, N., additional, Recondo, G., additional, Berthou, H., additional, Fabre-Guillevin, E., additional, Laguna Montes, J.C., additional, Blaquier, J.B., additional, Jimenez Munarriz, B.E., additional, Tagliamento, M., additional, Sacco, G., additional, Minatta, J.N., additional, Girard, N., additional, Moran Bueno, M.T., additional, López Castro, R., additional, Besse, B., additional, and Mezquita, L., additional

Published
2022
Full Text
View/download PDF

12. Representatividad del Registro de Tumores Torácicos de España. Comparación de datos sociodemográficos con otros registros nacionales

Author

Candal-Pedreira C, Ruano-Ravina A, Carcereny E, Rodríguez-Abreu D, Guirado-Risueño M, López-Castro R, Massutí B, Blasco A, Ortega AL, and Provencio M

Subjects
Age, Cáncer de pulmón, Spain, Registro de tumores, España, Edad, Sex, Cancer registry, Lung cancer, Sexo
Abstract

OBJECTIVE: In Spain, due to the lack of data at national level a lung cancer registry, the Thoracic Tumour Registry (TTR), was created. Such registry should demonstrate comparability with population-based data to ensure representativeness at population level. The aim is to compare the socio-demographic characteristics of the TTR with incidence data from the Red de Registros de Cáncer (REDECAN) and mortality data from the Instituto Nacional de Estadística (INE). METHOD: Lung cancer data sources available to date, REDECAN and INE, were used. Lung cancer cases overall and disaggregated by sex and age groups were collected from each source of information and data were compared for the period 2017-2020. Sex and age group proportions of TTR were calculated for both databases (which collect incidence and mortality data), for the entire study period and broken down by year. RESULTS: A total of 17,109 incident lung cancer cases from the TTR, 58,668 estimated incident cases from REDECAN and 88,083 deaths registered from INE between 2017 and 2020 were included. In terms of sex, the proportions are very similar between the three sources and the differences do not exceed 4%. In terms of age, the differences are not large, being larger for mortality data in the older age group from the INE versus the TTR. CONCLUSIONS: The TTR seems to be representative of lung cancer cases diagnosed in Spain between 2019 and 2020, both by sex and age. This allows us to accurately characterise the status of this disease, which is the leading cause of cancer death in Spain, and that the analysis of results obtained from the RTT can be applied to cases of lung cancer diagnosed in our country.

Published
2022

13. A prognostic score for patients with malignant pleural mesothelioma (MPM) receiving second-line immunotherapy or chemotherapy in the ETOP 9–15 PROMISE-meso phase III trial

Author

Luigi Banna, G. Addeo, A. Zygoura, P. Tsourti, Z. Popat, S. Curioni-Fontecedro, A. Nadal, E. Shah, R. Pope, A. Fisher, P. Spicer, J. Roy, A. Gilligan, D. Gautschi, O. Janthur, W.-D. López-Castro, R. Roschitzki-Voser, H. Dafni, U. Peters, S. Stahel, R.A.

Abstract

Introduction: Clinical and laboratory parameters associated with response for patients with advanced pre-treated malignant pleural mesothelioma (MPM) are lacking. We aimed to identify prognostic and predictive markers among patients with relapsed MPM who were randomised into the ETOP 9–15 PROMISE-meso phase III trial, evaluating pembrolizumab and chemotherapy. Methods: Baseline clinical and laboratory parameters were investigated for prognostic or predictive value on progression-free survival (PFS) and overall survival (OS) in a retrospective analysis, based on the full cohort of 144 MPM patients. These consisted of immune-inflammatory indexes (neutrophil–lymphocyte ratio [NLR], systemic immune-inflammatory index [SII], lactate dehydrogenase [LDH]) along with other already known prognostic baseline characteristics and laboratory values. Cut-offs were chosen independently of outcome. Based on Cox multivariable analysis for PFS in the whole cohort, a risk factor model was built to illustrate the prognostic stratification of patients by the combination of the derived independent prognostic factors, taking into account the EORTC score, a validated prognostic score in MPM. All models were stratified by histology and adjusted by treatment. Results: In the stratified multivariable analysis in the whole cohort, high SII (hazard ratio (HR) 2.06; 95%CI 1.39–3.05) and low haemoglobin (HR 1.62; 95%CI 1.06–2.50) were associated with worse PFS. Based on these two prognostic factors, a mesothelioma risk score (MRS) was constructed with three PFS risk prognosis categories: favourable, intermediate and poor with 0, 1 and 2 risk factors, respectively (corresponding percent of cohort: 24%, 34% and 42% and median PFS: 5.8, 4.2 and 2.1 months). The derived MRS stratified the prognosis for PFS and OS, overall and within each of the EORTC groups. No significant predictors of treatment benefit were identified. Conclusions: The proposed MRS is prognostic of patient outcome and it fine-tunes the prognosis of patients with pre-treated MPM alone or when used with the already established EORTC score. © 2022

Published
2022

14. 1174P Sex differences in advanced melanoma in Spain: Results from the prospective real-world study GEM 1801

Author

Muñoz Couselo, E., Berciano-Guerrero, M-Á., Manzano, J.L., Soria, A., Cerezuela-Fuentes, P., Crespo, G., Antoñanzas, M., Puértolas, T., García Castaño, A., Gutiérrez Sanz, L., Espinosa, E., Ayala de Miguel, P., Majem, M., López Castro, R., Fernández-Morales, L.A., Rivas, B., Medina, J., Berrocal, A., Martín Algarra, S., and Márquez-Rodas, I.

Published
2023
Full Text
View/download PDF

15. 1114P Encorafenib (E) plus binimetinib (B) in unresectable advanced or metastatic BRAFV600-mut melanoma, real-world evidence in Spain (GEM 2002 - BECARE)

Author

Soria, A., Sanchez Mauriño, P., García Galindo, R., Sequero, S., Gutiérrez Sanz, L., Crespo, G., Díaz-Beveridge, R., Puértolas, T., López, P., Fra Rodríguez, J., López Castro, R., Aguayo, C., Valdivia, J., Cunquero-Tomás, A., Benítez, G., Ayala de Miguel, P., Espinosa, E., Muñoz-Couselo, E., Campos, B., and Cerezuela-Fuentes, P.

Published
2023
Full Text
View/download PDF

18. LIPI and outcomes of durvalumab as consolidation therapy after ChRT in patients with locally-advanced NSCLC [MA08.04]

Author

Riudavets, M., Mezquita, L., Auclin, E., Benitez, J.C., Le Pechoux, C., Majem, M., Dempsey, N., Lobefaro, R., Nadal, E., Amores, A., Menis, J., Tagliamento, M., López-Castro, R., Ponce, S., Bosch-Barrera, J., Aboubakar Nana, Frank, Mosquera, J., Pilotto, S., Reyes, R., Mielgo, X., Duchemann, B., Mosteiro, M., Mussat, E., De Giglio, A., Scheffler, M., Campayo, M., Botticella, A., Naltet, C., Lavaud, P., Lopes, G., Signorelli, D., Garcia-Campelo, R., Besse, B., Planchard, D., 2020 World Conference on Lung Cancer, UCL - SSS/IREC/PNEU - Pôle de Pneumologie, ORL et Dermatologie, and UCL - (SLuc) Service de pneumologie

Subjects
Pulmonary and Respiratory Medicine, Oncology
Abstract

INTRODUCTION : The lung immune prognostic index (LIPI), which combines pretreatment derived neutrophils/[leukocytes minus neutrophils] ratio (dNLR) >3 and lactate dehydrogenase (LDH) > upper limit of normal (ULN), is associated with outcomes in advanced non-small cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitors (ICI). We aimed to assess whether pretreatment LIPI correlates with durvalumab efficacy after concurrent chemoradiotherapy in the locally advanced setting.

Published
2021

21. P09.16 Immunotherapy for Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC). Real-Life Experience from Castile and Leon

Author

Valdivieso, S. Medina, primary, Antón, C. Bayona, additional, Hernández, L. Bellido, additional, López-Castro, R., additional, González, M. Fernández, additional, García, A. Reyes, additional, Serrano, A. Díaz, additional, Herrera, B. Esteban, additional, Cousido, L. Sánchez, additional, Bravo, R. Gómez, additional, Del Barco, E., additional, Cuadrado-Albite, E., additional, Vallejo-Pascual, M., additional, De Frutos González, B., additional, Cornejo, R. Escala, additional, Peña, T. García, additional, Piedra, M. Rojas, additional, De La Torre Lázaro, S., additional, Martín, E. Escalera, additional, and Taín, P. Diz, additional

Published
2021
Full Text
View/download PDF

22. MA08.04 LIPI and outcomes of durvalumab as consolidation therapy after ChRT in patients with locally-advanced NSCLC

Author

Riudavets, M., primary, Mezquita, L., additional, Auclin, E., additional, Benitez, J.C., additional, Le Pechoux, C., additional, Majem, M., additional, Dempsey, N., additional, Lobefaro, R., additional, Nadal, E., additional, Amores, A., additional, Menis, J., additional, Tagliamento, M., additional, López-Castro, R., additional, Ponce, S., additional, Bosch-Barrera, J., additional, Aboubakar, F., additional, Mosquera, J., additional, Pilotto, S., additional, Reyes, R., additional, Mielgo, X., additional, Duchemann, B., additional, Mosteiro, M., additional, Mussat, E., additional, De Giglio, A., additional, Scheffler, M., additional, Campayo, M., additional, Botticella, A., additional, Naltet, C., additional, Lavaud, P., additional, Lopes, G., additional, Signorelli, D., additional, Garcia-Campelo, R., additional, Besse, B., additional, and Planchard, D., additional

Published
2021
Full Text
View/download PDF

23. MA03.08 Impact of COVID-19 Pandemic in the Diagnosis and Prognosis of Lung Cancer

Author

Reyes, R., primary, López-Castro, R., additional, Auclin, E., additional, García, T., additional, Chourio, M.J., additional, Rodriguez, A., additional, López, L., additional, Laguna, J.C., additional, Lucena, C., additional, Molins, L., additional, Martínez, D., additional, Casas, F., additional, Mayoral, M., additional, Teixidó, C., additional, Prat, A., additional, Viñolas, N., additional, Reguart, N., additional, and Mezquita, L., additional

Published
2021
Full Text
View/download PDF

24. P52.05 Lung Cancer Symptoms at Diagnosis: Data from the Thoracic Tumors Registry (TTR Study).

Author

Calvo, V., primary, Ruano-Ravina, A., additional, Carcereny, E., additional, Moran, T., additional, Rodríguez-Abreu, D., additional, López-Castro, R., additional, Cuadrado-Albite, E., additional, Guirado, M., additional, Gomez-Gonzalez, L., additional, Massuti, B., additional, Granados, A.L. Ortega, additional, Blasco, A., additional, Dols, M. Cobo, additional, Mosquera, J., additional, Hernandez-Martinez, A., additional, Trigo, J., additional, Juan, O., additional, De La Rosa, C. Aguado, additional, Gómez, M. Dómine, additional, Sala, M., additional, Oramas, J., additional, Ojea, C. Gonzalez, additional, Cerezo, S., additional, and Provencio, M., additional

Published
2021
Full Text
View/download PDF

25. A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial

Author

Popat, S. Curioni-Fontecedro, A. Dafni, U. Shah, R. O'Brien, M. Pope, A. Fisher, P. Spicer, J. Roy, A. Gilligan, D. Gautschi, O. Nadal, E. Janthur, W.D. López Castro, R. García Campelo, R. Rusakiewicz, S. Letovanec, I. Polydoropoulou, V. Roschitzki-Voser, H. Ruepp, B. Gasca-Ruchti, A. Peters, S. Stahel, R.A.

Abstract

Background: Malignant pleural mesothelioma (MPM) is an aggressive malignancy characterised by limited treatment options and a poor prognosis. At relapse after platinum-based chemotherapy, single-agent chemotherapy is commonly used and single-arm trials of immune-checkpoint inhibitors have demonstrated encouraging activity. Patients and methods: PROMISE-meso is an open-label 1:1 randomised phase III trial investigating the efficacy of pembrolizumab (200 mg/Q3W) versus institutional choice single-agent chemotherapy (gemcitabine or vinorelbine) in relapsed MPM patients with progression after/on previous platinum-based chemotherapy. Patients were performance status 0–1 and unselected for programmed cell death ligand 1 (PD-L1) status. At progression, patients randomly assigned to receive chemotherapy were allowed to crossover to pembrolizumab. The primary end point was progression-free survival (PFS), assessed by blinded independent central review (BICR). Secondary end points were overall survival (OS), investigator-assessed PFS, objective response rate (ORR), and safety. Efficacy by PD-L1 status was investigated in exploratory analyses. Results: Between September 2017 and August 2018, 144 patients were randomly allocated (pembrolizumab: 73; chemotherapy: 71). At data cut-off [20 February 2019, median follow-up of 11.8 months (interquartile range: 9.9–14.5)], 118 BICR-PFS events were observed. No difference in BICR-PFS was detected [hazard ratio = 1.06, 95% confidence interval (CI): 0.73–1.53; P = 0.76], and median BICR-PFS (95% CI) for pembrolizumab was 2.5 (2.1–4.2), compared with 3.4 (2.2–4.3) months for chemotherapy. A difference in ORR for pembrolizumab was identified (22%, 95% CI: 13% to 33%), over chemotherapy (6%, 95% CI: 2% to 14%; P = 0.004). Forty-five patients (63%) assigned to chemotherapy received pembrolizumab at progression. With follow-up to 21 August 2019 [17.5 months: (14.8–19.7)], no difference in OS was detected between groups (HR = 1.12, 95% CI: 0.74–1.69; P = 0.59), even after adjusting for crossover. Pembrolizumab safety was consistent with previous observations. Exploratory efficacy analyses by PD-L1 status demonstrated no improvements in ORR/PFS/OS. Conclusion: This is the first randomised trial evaluating the efficacy of pembrolizumab in MPM patients progressing after/on previous platinum-based chemotherapy. In biologically unselected patients, although associated with an improved ORR, pembrolizumab improves neither PFS nor OS over single-agent chemotherapy. © 2020 European Society for Medical Oncology

Published
2020

26. 1681P First results of the COCO study: COVID-19 outcomes in patients with cancer

Author

Seguí, E., primary, García de Herreros, M., additional, Auclin, E., additional, Mirallas, O., additional, Casadevall, D., additional, Rodriguez, M., additional, Epaillard, N., additional, Tagliamento, M., additional, Pilotto, S., additional, López-Castro, R., additional, Mielgo, X., additional, Urbano, C., additional, Pesántez, D., additional, Saoudi, N., additional, Bluthgen, M.V., additional, Masfarré, L., additional, Minatta, J.N., additional, Cruz, C.A., additional, Mezquita, L., additional, and Prat, A., additional

Published
2020
Full Text
View/download PDF

27. 1713P Active smoking and severity of COVID-19 infection in cancer patients

Author

Marta, G.D.H., primary, Auclin, E., additional, Saoudi Gonzalez, N., additional, Casadevall Aguilar, D., additional, Rodriguez Castells, M., additional, Epaillard, N., additional, Tagliamento, M., additional, Pilotto, S., additional, López-Castro, R., additional, Mielgo Rubio, X., additional, Urbano Centella, C., additional, Pineda, E., additional, Laia, F.M., additional, Mirallas, O., additional, Bluthgen, M.V., additional, Masfarré, L., additional, Minatta, J.N., additional, Cruz, C.A., additional, Prat, A., additional, and Mezquita, L., additional

Published
2020
Full Text
View/download PDF

28. 1714P Change of circulating pro-inflammatory markers between pre-COVID-19 condition and COVID-19 diagnosis predicts early death in cancer patients: The FLARE score

Author

Seguí, E., primary, Auclin, E., additional, Casadevall, D., additional, Aguilar-Company, J., additional, Rodriguez, M., additional, Epaillard, N., additional, Tagliamento, M., additional, Pilotto, S., additional, López-Castro, R., additional, Mielgo, X., additional, Urbano, C., additional, Rodríguez, A., additional, García-Illescas, D., additional, Bluthgen, M.V., additional, Masfarré, L., additional, Oliveres, H., additional, Minatta, J.N., additional, Marco-Hernández, J., additional, Prat, A., additional, and Mezquita, L., additional

Published
2020
Full Text
View/download PDF

29. A multicentre randomized phase III trial comparing pembrolizumab (P) vs single agent chemotherapy (CT) for advanced pre-treated malignant pleural mesothelioma (MPM): Results from the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial

Author

Popat, S., primary, Curioni-Fontecedro, A., additional, Polydoropoulou, V., additional, Shah, R., additional, O’Brien, M., additional, Pope, A., additional, Fisher, P., additional, Spicer, J., additional, Roy, A., additional, Gilligan, D., additional, Gautschi, O., additional, Nadal, E., additional, Janthur, W.-D., additional, López Castro, R., additional, García Campelo, R., additional, Roschitzki-Voser, H., additional, Ruepp, B., additional, Rusakiewicz, S., additional, Peters, S., additional, and Stahel, R.A., additional

Published
2019
Full Text
View/download PDF

30. Biomarker testing of lung cancer in Spain

Author

Rodriguez Abreu, D., primary, Guirado, M., additional, Camps Herrero, C.J., additional, Bosch Barrera, J., additional, Bernabé, R., additional, Casal, J., additional, García-Campelo, M.-R., additional, Gonzalez-Larriba, J.L., additional, Massuti Sureda, B., additional, Ortega Granados, A.L., additional, Domine Gomez, M., additional, Sala, M.A., additional, Padilla, A., additional, Del Barco Morillo, E., additional, Oramas Rodriguez, J.M., additional, Blanco Guerrero, R., additional, Aguiar Bujanda, D., additional, López Castro, R., additional, Carcereny Costa, E., additional, and Provencio, M., additional

Published
2019
Full Text
View/download PDF

31. Applicability of lung immune prognostic index (LIPI) to predict efficacy of first-line pembrolizumab in advanced non-small cell lung cancer (NSCLC)

Author

Mielgo Rubio, X., primary, Gomez Rueda, A., additional, Antoñanzas, M., additional, Falagan, S., additional, Núñez, J.A., additional, Sánchez Peña, A.M., additional, Gómez-Barreda, I., additional, Martinez Moreno, E., additional, Cerezo Gonzalez, S., additional, Cabezón Gutiérrez, L., additional, Sanchez Torres, J.M., additional, Jimenez Munarriz, B.E., additional, Cervera, R., additional, Pangua Mendez, C., additional, Calles Blanco, A., additional, Lopez Martin, A., additional, López Castro, R., additional, Sotelo Lezama, M.J., additional, Pérez Fernández, E., additional, and Cruz, P., additional

Published
2019
Full Text
View/download PDF

32. First analysis of patients (p) with stage IV non-small cell lung cancer (NSCLC) of the thoracic tumor registry (RTT) of the Spanish Lung Cancer Group (SLCG)

Author

Carcereny Costa, E., primary, Rodriguez-Abreu, D., additional, Guirado, M., additional, López-Castro, R., additional, Massutí, B., additional, Bosch Barrera, J., additional, Nogueron Martnez, E., additional, Sala Gonzalez, M.A., additional, Domine Gomez, M., additional, Del Barco Morillo, E., additional, Cerezo Gonzalez, S., additional, Dorta Suarez, M., additional, Casal Rubio, J., additional, Camps, C., additional, Muñoz, M.A., additional, de las Peñas, R., additional, Ortega dominguez, J.A., additional, Gonzalez-Larriba, J.L., additional, Bernabe Caro, R., additional, and Provencio Pulla, M., additional

Published
2018
Full Text
View/download PDF

33. Neutrophil-platelet score (NPS), a predictive systemic inflammation score for PD-1 immune checkpoint inhibitors (ICI) in pretreated advanced non-small cell lung cancer (NSCLC) patients

Author

Mielgo Rubio, X., primary, Sereno Moyano, M., additional, Chara, L.E., additional, López-Castro, R., additional, Rubio-Martínez, J., additional, Velastegui, A., additional, Olier-Garate, C., additional, Falagán, S., additional, Gómez-Barreda, I., additional, Riquelme, A., additional, Silva-Ruiz, J., additional, Moreno-Rubio, J., additional, López, C., additional, Bueno, C., additional, Cardeña, A., additional, Pérez-Fernández, E., additional, Martí-Castelló, M.P., additional, and Sotelo-Lezama, M.J., additional

Published
2018
Full Text
View/download PDF

34. Phase II multicenter, single arm, open label study of nivolumab in combination with ipilimumab in untreated patients with metastatic uveal melanoma (GEM1402.NCT02626962)

Author

Piulats Rodriguez, J.M., primary, De La Cruz Merino, L., additional, Espinosa, E., additional, Alonso Carrión, L., additional, Martin Algarra, S., additional, López-Castro, R., additional, Curiel García, M.T., additional, Rodriguez Abreu, D., additional, Rullan Iriarte, A.J., additional, and Berrocal Jaime, A., additional

Published
2018
Full Text
View/download PDF

35. OA14.01 Family History of Cancer and Lung Cancer: Information from the Thoracic Tumors Registry (TTR Study)

Author

Calvo, V., Carcereny, E., Abreu, D. Rodriguez, Lopez-Castro, R., Guirado, M., Camps, C., Cobo, M., Ortega, A.L., Bernabé, R., Massuti, B., Mosquera, J., Del Barco, E., Gonzalez - Larriba, J.L., Bosch - Barrera, J., Ojeda, C. Gonzalez, Domine, M., Juan, O., Martínez-Cutillas, M., Benítez, G., Collazo-Lorduy, A., Cucurull, M., and Provencio, M.

Published
2021
Full Text
View/download PDF

36. 1056P Survival of patients with advanced melanoma according to first-line treatment and key prognostic factors: Real-world data from GEM1801 study

Author

Marquez-Rodas, I., Berciano Guerrero, M.A., Muñoz Couselo, E., Manzano, J.L., Crespo Herrero, G., Soria, A., Cerezuela, P., Puertolas Hernandez, T., Berrocal, A., Majem Tarruella, M., Bellido Hernández, L., Espinosa, E., Garcia Castano, A., Medina Martínez, J., Fernandez Morales, L.A., Aguado de la Rosa, C., Gutierrez Sanz, L., Lopez Castro, R., Ayala de Miguel, P., and Martin Algarra, S.

Published
2021
Full Text
View/download PDF

37. FP07.06 Lung Immune Prognostic Index (LIPI) in Advanced NSCLC Patients Treated with Immunotherapy, Chemotherapy and both Combined Upfront.

Author

Blanc-Durand, F., Mielgo Rubio, X., Auclin, E., Ponce-Aix, S., Lopez Castro, R., Nadal, E., Planchard, D., Routy, B., Hendriks, L., Sullivan, I., Dempsey, N., Pilotto, S., Aboubakar, F., Pinato, D.J., Castonguay, M., Rodriguez, A., Amores, A., Bluthgen, M.V., Duchemann, B., Castellano, P. Cruz, Aguado De La Rosa, C., Sereno Moyano, M., Ruffinelli, J., Lopez, G., Caramella, C., Besse, B., and Mezquita, L.

Published
2021
Full Text
View/download PDF

38. 1726P Expanding the role of medical oncologist in the management of COVID-19

Author

Ghiglione, L., Auclin, E., Aguilar-Company, J., Epaillard, N., Casadevall Aguilar, D., Masfarré, L., Rodriguez Castells, M., Tagliamento, M., Pilotto, S., Lopez Castro, R., Mielgo Rubio, X., Urbano Centella, C., Laguna, J.C., García-Illescas, D., Bluthgen, M.V., Gorría Puga, T., Minatta, J.N., Cruz, C.A., Prat, A., and Mezquita, L.

Published
2020
Full Text
View/download PDF

39. 1794P Extensive stage (ES) small-cell lung cancer (SCLC) in Spain: A review of demographic, epidemiological and clinical data from the Thoracic Tumors Registry (TTR study)

Author

Calvo, V., Carcereny Costa, E., Guirado, M., Ortega Granados, A.L., Lopez Castro, R., Rodriguez-Abreu, D., Garcia Campelo, R., del Barco Morillo, E., Juan-Vidal, O., Camps, C.J., Gonzalez-Larriba, J.L., Domine Gomez, M., Trigo Perez, J.M., Cobo Dols, M., Cerezo Gonzalez, S., Calzas Rodriguez, J., Massuti Sureda, B., Bosch-Barrera, J., Moran, T., and Provencio Pulla, M.

Published
2020
Full Text
View/download PDF

40. 1786P Small cell lung cancer (SCLC) extensive stage (ES) in Spain: Efficacy of treatments, data from the thoracic tumours registry (TTR study)

Author

Carcereny Costa, E., Calvo, V., Guirado, M., Ortega Granados, A.L., Lopez Castro, R., Rodriguez-Abreu, D., Mosquera Martinez, J., del Barco Morillo, E., Juan-Vidal, O., Sanchez Hernandez, A., Sala Gonzalez, M.A., Blanco Guerrero, R., Bernabe Caro, R., Alonso, R., Garcia Benito, C., Oramas Rodriguez, J.M., Diz Tain, P., Nogueron Martinez, E., Guirao Rubio, C.M., and Provencio Pulla, M.

Published
2020
Full Text
View/download PDF

41. LBA91_PR - A multicentre randomized phase III trial comparing pembrolizumab (P) vs single agent chemotherapy (CT) for advanced pre-treated malignant pleural mesothelioma (MPM): Results from the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial

Author

Popat, S., Curioni-Fontecedro, A., Polydoropoulou, V., Shah, R., O’Brien, M., Pope, A., Fisher, P., Spicer, J., Roy, A., Gilligan, D., Gautschi, O., Nadal, E., Janthur, W.-D., López Castro, R., García Campelo, R., Roschitzki-Voser, H., Ruepp, B., Rusakiewicz, S., Peters, S., and Stahel, R.A.

Published
2019
Full Text
View/download PDF

42. 1846P - Biomarker testing of lung cancer in Spain

Author

Rodriguez Abreu, D., Guirado, M., Camps Herrero, C.J., Bosch Barrera, J., Bernabé, R., Casal, J., García-Campelo, M.-R., Gonzalez-Larriba, J.L., Massuti Sureda, B., Ortega Granados, A.L., Domine Gomez, M., Sala, M.A., Padilla, A., Del Barco Morillo, E., Oramas Rodriguez, J.M., Blanco Guerrero, R., Aguiar Bujanda, D., López Castro, R., Carcereny Costa, E., and Provencio, M.

Published
2019
Full Text
View/download PDF

43. 1848P - Spanish registry of thoracic tumors (TTR): Interim analyses of comorbidities, risk associations, personal and family history of cancer

Author

Lopez Castro, R., Lianes, P., Nogueron Martnez, E., Diz Tain, P., Calzas, J., Juan Vidal, O.J., Sereno Moyano, M., Muñoz, M.A., Guillot Morales, M., Capdevila Riera, L., Campillo Fuentes, J.A., Valdivia-Bautista, J., Cobo Dols, M., Paredes Lario, A., Mielgo Rubio, X., Majem Tarruella, M., Martínez, M., Sanchez Torres, J.M., Rubio-Viqueira, B., and Provencio, M.

Published
2019
Full Text
View/download PDF

44. 1845P - Tobacco use in lung cancer (LC) patients (p) in Spain

Author

Carcereny Costa, E., Guirado, M., Camps Herrero, C.J., Bosch Barrera, J., García-Campelo, M.-R., Ortega Granados, A.L., Gonzalez-Larriba, J.L., De Dios Alvare, N., Domine Gomez, M., Massuti Sureda, B., Sala, M.A., Bernabé, R., Oramas Rodriguez, J.M., del Barco Morillo, E., Padilla, A., Aguiar Bujanda, D., Cerezo Gonzalez, S., Lopez Castro, R., Rodriguez Abreu, D., and Provencio, M.

Published
2019
Full Text
View/download PDF

45. 1509P - Applicability of lung immune prognostic index (LIPI) to predict efficacy of first-line pembrolizumab in advanced non-small cell lung cancer (NSCLC)

Author

Mielgo Rubio, X., Gomez Rueda, A., Antoñanzas, M., Falagan, S., Núñez, J.A., Sánchez Peña, A.M., Gómez-Barreda, I., Martinez Moreno, E., Cerezo Gonzalez, S., Cabezón Gutiérrez, L., Sanchez Torres, J.M., Jimenez Munarriz, B.E., Cervera, R., Pangua Mendez, C., Calles Blanco, A., Lopez Martin, A., López Castro, R., Sotelo Lezama, M.J., Pérez Fernández, E., and Cruz, P.

Published
2019
Full Text
View/download PDF

46. Risk model for clinically relevant neutropenic event among patients with non hematological tumors receiving chemotherapy regimens not classified as high-risk for febrile neutropenia: results from a multicenter prospective cohort study (NEURISK)

Author

Muñoz-Langa, J., primary, Borrega, P., additional, García-Bueno, J.M., additional, Purificación Martínez del Prado, P., additional, Campos, J.M., additional, Quindos, M., additional, López Castro, R., additional, Valentí Moreno, V., additional, Jiménez Orozco, E., additional, and Lazaro, M., additional

Published
2016
Full Text
View/download PDF

47. 1479P - First analysis of patients (p) with stage IV non-small cell lung cancer (NSCLC) of the thoracic tumor registry (RTT) of the Spanish Lung Cancer Group (SLCG)

Author

Carcereny Costa, E., Rodriguez-Abreu, D., Guirado, M., López-Castro, R., Massutí, B., Bosch Barrera, J., Nogueron Martnez, E., Sala Gonzalez, M.A., Domine Gomez, M., Del Barco Morillo, E., Cerezo Gonzalez, S., Dorta Suarez, M., Casal Rubio, J., Camps, C., Muñoz, M.A., de las Peñas, R., Ortega dominguez, J.A., Gonzalez-Larriba, J.L., Bernabe Caro, R., and Provencio Pulla, M.

Published
2018
Full Text
View/download PDF

48. 1413P - Neutrophil-platelet score (NPS), a predictive systemic inflammation score for PD-1 immune checkpoint inhibitors (ICI) in pretreated advanced non-small cell lung cancer (NSCLC) patients

Author

Mielgo Rubio, X., Sereno Moyano, M., Chara, L.E., López-Castro, R., Rubio-Martínez, J., Velastegui, A., Olier-Garate, C., Falagán, S., Gómez-Barreda, I., Riquelme, A., Silva-Ruiz, J., Moreno-Rubio, J., López, C., Bueno, C., Cardeña, A., Pérez-Fernández, E., Martí-Castelló, M.P., and Sotelo-Lezama, M.J.

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results